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Abstract: Background Despite their low individual metastatic potential, thin melanomas (฀ 1 mm Breslow
thickness) contribute significantly to melanoma mortality overall. Therefore, identification of prognostic
biomarkers is particularly important in this subgroup of melanoma. Prompted by pre‐clinical results,
we investigated cyclin D1 protein and Ki‐67 expression in in situ, metastatic and non‐metastatic thin
melanomas. Material and Methods Immunohistochemistry was performed on 112 melanoma specimens,
thereof 22 in situ, 48 non‐metastatic and 42 metastatic thin melanomas. Overall, epidermal and dermal
cyclin D1 and Ki‐67 expression were semi‐quantitatively evaluated by three independent investigators
and compared between groups. Results Epidermal Ki‐67 expression did not differ statistically in in
situ and invasive melanoma (P = 0.7). Epidermal cyclin D1 expression was significantly higher in thin
invasive than in in situ melanoma (P = 0.003). No difference was found in cyclin D1 expression between
metastatic and non‐metastatic invasive tumours. Metastatic and non‐metastatic thin melanomas did
not show significant differences in epidermal expression of Ki‐67 and cyclin D1 (P = 0.148 and P =
0.611, respectively). In contrast, strong dermal expression of Ki‐67 was more frequent in metastatic
than non‐metastatic samples (28.6 vs. 8.3%, respectively, P = 0.001). The prognostic value of dermal
Ki‐67 expression was confirmed by multivariate analysis (P = 0.047). Conclusion We found an increased
expression of cyclin D1 invasive thin melanomas compared to in situ melanomas which supports a potential
role of this protein in early invasion in melanoma, as suggested by pre‐clinical findings. Moreover, our
results confirm that high dermal Ki‐67 expression is associated with an increased risk of metastasis
development in thin melanoma and could possibly serve as a prognostic biomarker in clinical practice,
especially if combined with additional methods.
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ABSTRACT
Background
Despite their low individual metastatic potential, thin melanomas ( 1 mm Breslow 
thickness) contribute significantly to melanoma mortality overall. Therefore, identification 
of prognostic biomarkers is particularly important in this subgroup of melanoma. 
Prompted by pre-clinical results, we investigated cyclin D1 protein and Ki-67 expression 
in in situ, metastatic and non-metastatic thin melanomas. 
Material and Methods
Immunohistochemistry was performed on 112 melanoma specimens, thereof 22 in situ, 
48 non-metastatic and 42 metastatic thin melanomas. Overall, epidermal and dermal 
cyclin D1 and Ki-67 expression were semi-quantitatively evaluated by three independent 
investigators and compared between groups.
Results
Epidermal Ki-67 expression did not differ statistically in in situ and invasive melanoma 
(P = 0.7). Epidermal cyclin D1 expression was significantly higher in thin invasive than in 
in situ melanoma (P = 0.003). 
No difference was found in cyclin D1 expression between metastatic and non-metastatic 
invasive tumours. Metastatic and non-metastatic thin melanomas did not show significant 
differences in epidermal expression of Ki-67 and cyclin D1 (P = 0.148 and P = 0.611, 
respectively). In contrast, strong dermal expression of Ki-67 was more frequent in 
metastatic than non-metastatic samples (28.6 vs. 8.3%, respectively, P = 0.001). The 
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Conclusion
We found an increased expression of cyclin D1 invasive thin melanomas compared to in 
situ melanomas which supports a potential role of this protein in early invasion in 
melanoma, as suggested by pre-clinical findings. Moreover, our results confirm that high 
dermal Ki-67 expression is associated with an increased risk of metastasis development 
in thin melanoma and could possibly serve as a prognostic biomarker in clinical practice, 
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INTRODUCTION
The incidence of invasive cutaneous melanoma has been steadily increasing in countries 
of the western world for more than five decades (1). Owing to improved skin cancer 
screening and diagnostic techniques, the majority of cutaneous primary melanomas is 
diagnosed at an in situ or early invasive stage. Despite the low individual metastatic 
potential of these tumours, the subgroup of thin invasive melanomas (up to 1 mm in 
Breslow thickness) accounts for the highest absolute number of melanoma-related 
deaths of all four T subcategories as defined by the American Joint Committee on Cancer 
(AJCC) staging system (2-4). Hence, understanding of the early cellular and genetic 
mechanisms that enable melanoma cells to breach the basement membrane and acquire 
invasive potential is crucial to allow for early identification of selected patients at 
increased risk of developing metastatic disease. In regard to genetics, melanoma 
development has been described as a distinct step-wise process with a successive 
evolution from unequivocally benign to intermediate, early malignant (in situ) and invasive 
malignant melanocytic lesions based on distinct alterations, including initial BRAF V600E 
mutations amongst others (5). The diverse cellular consequences of these oncogenic 
mutations that confer tumour growth, invasion and metastatic potential constitute the 
well-known hallmarks of cancer (6). One of these hallmarks is sustained proliferative 
signalling which in vivo can be depicted through detection of proliferation markers such 
as the Ki-67 protein. This protein is expressed in the nuclei of cells in the G1, S, and G2 
phase of the cell cycle as well as in mitosis (7). The functional significance of the Ki-67 
protein within the cell cycle remains to be fully elucidated. Important roles in cancer stem 
cell maintenance and organization of the chromosome periphery during mitosis have 
been described. Clinically, increased Ki-67 expression is a well-known marker of poor 
prognosis in various malignancies such as breast cancer (8). In melanoma, its prognostic 
role was most clearly shown in thick primary tumours (Breslow > 1 mm) (9, 10). In thin 
primary melanomas, particularly high dermal Ki-67 expression has been associated with 
increased risk for metastasis development (11).
Another potential marker of tumour cell proliferation is cyclin D1. This highly labile protein 
regulates G1/S transition in the cell cycle through interaction with cyclin-dependent 
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to increased proliferation amongst other cellular changes (12, 13). The CCND1 gene 
encoding for cyclin D1 is an established oncogene amplified in a variety of tumours such 
as breast, lung or endometrial cancer (12). Increased expression of cyclin D1 has also 
been reported in up to 62% of primary melanomas, while being minimal in melanocytic 
nevi (14). The oncogenic effect of cyclin D1 overexpression or gene amplification is 
primarily attributed to its impact on tumour cell proliferation, but also proliferation-
independent oncogenic mechanisms have been proposed (12). These include effects of 
cyclin D1 on cellular migration and invasion, which were first described in macrophages 
(15). In this context, pre-clinical studies at our institution have shown that expression of 
cyclin D1 may confer early invasive properties of melanoma cells. As results concerning 
the prognostic significance of cyclin D1 expression in melanoma are inconsistent (16-19), 
based on our preclinical data, we hypothesized that cyclin D1 expression in primary 
melanoma may not merely be a surrogate for cellular proliferation, but also for early 
invasive properties of melanoma cells. Therefore, the present study investigated the 
expression and correlation of cyclin D1 and Ki-67 at different stages in the stepwise 
development of invasive melanoma. Both in situ and thin invasive primary melanomas 
were examined. Additionally, thin primary melanomas leading to the development of 
metastatic disease were specifically analysed in order to explore the potential role of 
cyclin D1 later in the process of invasion and metastasis development, hence re-
evaluating its potential as a prognostic marker.
MATERIALS & METHODS
Patient selection and Data collection
The study was approved by both local ethics committees (Zurich [KEK-ZH-No. 647 and 
800] and Salzburg [E-Nr. 2252]) prior to collection of data and tissue specimens. Clinical 
information was stored and analysed after encryption.
The study cohort consisted of patients with in situ (MIS), metastatic (MTM) and non-
metastatic (NMTM) thin melanomas diagnosed in the period from 2008 and 2016 at two 
melanoma reference centres in Zurich and Salzburg. Disease stage was classified 
according to the 7th edition of AJCC staging system (20). Patients with multiple primaries, 
uveal or mucosal melanoma were excluded. Epidemiological, clinical and laboratory 
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pathological institutes in and around Zurich and an external collaborating pathology 
institute (Salzburg) served as sources for formalin-fixed paraffin-embedded (FFPE) 
samples of the respective primary tumours. 
Immunohistochemistry (IHC)
Four different analyses (including H&E stain) were conducted on 3 μm thick FFPE-
sections. Processing comprised of deparaffinization in xylene and rehydratation in 
decreasing ethanol concentrations, consecutive boiling for epitope retrieval in a 3-in-1 
target retrieval solution (TRS6 or 9, Dako®, Agilent Technologies, Santa Clara, CA, USA) 
in a pressure cooker for a total of 40 minutes, followed by cooling for 20 minutes and 
rinsing with deionized water. Further staining was performed using the automated Dako® 
Autostainer Plus platform (see Supplementary Table 6). The following primary antibody 
clones were used: HMB-45 Clone HMB45 (M0634), Ki-67 Clone MIB 1 (M7240) and 
Cyclin D1 Clone EP12 (M3642), all manufactured by Dako®, Agilent Technologies, Santa 
Clara, CA, USA. 
Immunoreactivity scoring
Three independent, blinded investigators (CK, PK and WK as a board certified 
dermatopathologist) performed semi-quantitative evaluation of all IHC stains resulting in a 
consensus-based score for each evaluation.
Based on previous studies (11), Ki-67 immunostaining was graded as low (≤ 20% positive 
neoplastic cells, score 1) and strong ( 20%, score 2). The consensus-based approach 
was particularly useful in tumours with a brisk immune infiltrate when distinction between 
Ki-67 positive dermal tumour cells and proliferating immune cells was necessary. This 
applied to 37 out of 90 primary tumours (41.1% of all invasive melanomas). 
Cyclin D1 immunostaining was evaluated regarding expression intensity and frequency of 
positive tumour cells separately and combined using a modified Allred score method (21); 
scores (0) were graded as negative, (1-2) as weak, (3-5) as moderate, and (6-8) as 
strong. Additionally, cyclin D1 and Ki-67 expression were summed up as a composite 
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Statistical analysis
Excel 2016 (Microsoft Corporation, Redmond, WA, USA) and SPSS for Windows 25.0 
(SPSS Inc., Chicago, IL, USA) were used for statistical analysis. Statistical significance 
was defined by a two-sided p-value of less than 0.05. Chi-square test was applied for 
comparisons between groups (MIS vs. invasive melanoma, NMTM vs. MTM) concerning 
nominally scaled variables, i.e. IHC expression intensities and patterns. For analyses of 
small subgroups, Fisher’s exact test was used, if applicable. For comparisons concerning 
metric variables, either the t-test or the Mann-Whitney-U-test were performed, depending 
on the assumed distribution of the respective variable. Multivariate analyses of potential 
prognostic factors were conducted through binary logistic regression. Pearson’s bivariate 
analysis was conducted to assess potential correlations.
RESULTS 
Data of 174 patients (65 MTM and 109 NMTM) was collected (see Supplementary Figure 
1). Thereof, 52 (80%) and 94 (86.2%) blocks could be obtained, respectively. Final 
analysis comprised of 42 (80.8%) samples in the MTM and 48 (51.1%) samples in the 
NMTM group, which remained after exclusion due to discrepant Breslow thickness or 
insufficient tissue material. In addition, 22 MIS samples were included for comparison 
between MIS and invasive melanoma.
Patient and tumour characteristics
The study population consisted of 54 women and 58 men (see Table 1). Mean age at first 
diagnosis ranged from 49 to 72 years in the respective subgroups. The distribution of age 
between subgroups differed significantly (P < 0.001), as did the distribution of gender (P = 
0.032). Median Breslow thickness was 0.78 mm for MTM and 0.59 mm for NMTM (P < 
0.001). Ulceration status was known in 94% of tumours. There was no significant 
difference between frequency of ulceration in tumours of the MTM (5%) and the NMTM 
(10%) subgroup (P = 0.45).
The predominant histological subtype of invasive melanoma was superficial spreading 
melanoma (SSM) with 55 out of 112 samples (49.1%), representing 57.1% of the MTM 
and 43.8% of the NMTM group. In MIS patients, SSM and lentigo maligna melanoma 
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35.7% of all MTMs were localised on the trunk, whereas NMTMs were most frequently 
detected on the lower extremity (31.2%). 
We did not detect a difference in mitotic rate (MR, documented as < 1 or ≥ 1 mitoses per 
mm2) comparing invasive MTM and NMTM. Increased MR was found in 11 of 42 patients 
(26%) in the MTM and in 9 of 48 patients (19%, P = 0.4) in the NMTM group, respectively. 
Sentinel lymph node biopsy (SLNB) was performed in a total of 22 out of 90 patients 
(24.4%) with invasive melanoma. SLNB was conducted in 38% of patients with MTM and 
12.5% of patients with NMTM. In MTM patients, the SLNB result was positive in 9 
patients (56%), while no patient in the NMTM group had a positive SLN (which would 
have been an exclusion criterion for this subgroup upfront).
Additional tumour characteristics of MTM and NMTM according to Breslow thickness can 
be found in Supplementary Tables 2-5.
Immunohistochemistry findings
The results of IHC findings in MIS, NMTM and MTM are summarized in Table 2.
First, epidermal expression of Ki-67 and cyclin D1 in MIS and invasive melanoma (MTM 
and NMTM grouped together) was analysed. No statistically significant difference in Ki-67 
expression was observed between groups (P = 0.7). In contrast, a significantly higher 
percentage of cyclin D1 positive tumour cells was found in thin invasive melanoma 
compared to MIS (P = 0.003, Figure 1). 
Second, epidermal and dermal expression in NMTM and MTM were compared. 
Epidermally, no difference was detected between both groups (P = 0.15 for Ki-67; 
P = 0.61 for cyclin D1). Cyclin D1 expression in the dermis was similar in both groups 
(P = 0.88). Contrarily, there was a significantly higher percentage of strong dermal Ki-67 
expression in MTM compared to NMTM (28.6 and 8.3%; P = 0.001, Figure 2).
Analysing dermal Ki-67 expression together with the established prognostic parameter 
mitotic rate did not alter this finding significantly (P = 0.003). The prognostic value of 
epidermal Ki-67 expression was retained (P = 0.047) when other prognostic factors 
(Breslow thickness) and potential confounders (age, gender) – which were significantly 
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no correlation between Breslow thickness and dermal Ki-67 expression neither overall 
(Pearson’s r = 0.17, P = 0.14), nor within the MTM subgroup (Pearson’s r = -0.14, P = 0.46).
When analysing melanoma subtypes, epidermal cyclin D1 expression appeared to be 
increased in SSM compared to LMM in univariate analysis (P = 0.02). Also, there was a 
trend towards increased epidermal cyclin D1 expression in the small subgroup of acral 
lentiginous melanoma (ALM, 6 patients) compared to both SSM (P = 0.07) and LMM (P = 
0.07), see Table 3. 
Marginal note: Breslow measurement
Breslow thickness was re-measured for every sample obtained. As described above, 7 
out of 174 specimens (4% of the total of MTM and NMTM) had to be excluded due initial 
underestimation of tumour thickness. Median mismeasurement was 0.75 mm (95% CI = 
0.55 - 0.95).
In our study cohort (MTM and NMTM only, n = 90), documented Breslow was higher than 
the re-measured value in 32, lower in 36 and equal in 22 samples (35.6, 40 and 24.4%, 
respectively). Median discrepancy was 0.10 mm (95% CI = 0.07 - 0.13) and 0.14 mm (95% 
CI = 0.10 - 0.18).
DISCUSSION
Thin melanomas less than one millimetre in Breslow index do rarely metastasize, but, 
owing to their high incidence, still lead to a higher overall number of melanoma-related 
deaths than high-risk melanomas four millimetre or more in thickness (2, 3). The median 
duration between first melanoma diagnosis and death appears to be significantly longer 
in patients with thin primaries compared to those with thicker tumours (3). This may be 
explained by the more aggressive biology of thicker melanomas but may also result from 
later diagnosis of metastasis in patients with thin primaries. Late diagnosis of metastasis 
in turn could be the consequence of less stringent follow-up protocols in so-called low-
risk patients with thin melanoma. Since more rigorous follow-up does not seem justifiable 
in this patient population, the discovery of biomarkers predictive of metastasis in thin 
melanoma is of utmost importance. The present study aimed to re-evaluate the predictive 
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Our findings suggest that high dermal Ki-67 expression is an independent prognostic 
marker associated with an increased risk of metastasis formation in thin melanoma. This 
is in line with a large study by Gimotty et al. who also reported dermal, but not overall Ki-
67 expression to be an independent prognostic marker in a cohort of 396 patients with 
more than 10 years of follow-up (11). Despite its significance, there are certain caveats 
for the use of Ki-67 in clinical practice. As mentioned in the methods section, it is 
frequently difficult to distinguish proliferating dermal tumour cells from proliferating 
immune cells in single antibody Ki-67 IHC, i.e. tumour infiltrating lymphocytes. Hence, 
double-staining IHC with a melanocytic differentiation marker such as Melan-A or MART-
1 could increase sensitivity and specificity of Ki-67 staining. Combination with methods 
such as gene expression signatures could further augment prognostic value (22), albeit 
validity of such signatures remains to be confirmed in larger prospective studies.
Gimotty and others (11, 23-25) also reported on the prognostic potential of increased 
mitotic rate in thin melanoma, which previously was also included in the AJCC staging 
system (20). In our cohort of thin melanomas, we could not confirm the prognostic 
potential of mitotic rate, since increased mitoses were rare in both the metastatic and 
non-metastatic subgroup. 
Investigating the stepwise development of melanoma from in situ to invasive lesions, we 
found statistically significant differences in epidermal cyclin D1 expression between in 
situ and invasive melanomas. These results contrast some studies on cyclin D1, which 
reported weak expression in more than two thirds of melanoma samples and no 
expression in nevi, respectively, but are in accordance with other reports describing 
overall high expression in melanocytic lesions (16, 26, 27). Ramirez et al. evaluated 126 
pigmented skin lesions (thereof 28 in situ, 30 primary invasive, and 29 metastatic 
melanomas). They found a higher rate of cyclin D1 expression in invasive and in situ 
melanoma compared with benign melanocytic lesions. Contrary to our findings, these 
authors found an increased cyclin D1 expression in melanoma in situ compared to 
invasive melanoma, which could be explained by the higher number of melanomas over 
1 mm Breslow thickness in this study, since the latter tumours showed a trend towards 
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The proto-oncogenic role of cyclin D1 has been characterized in various studies (16-19). 
We propose that our immunohistochemical finding of an increased cyclin D1 expression 
in thin invasive melanoma also suggests a potential role of cyclin D1 during the process 
of invasion in the stepwise evolution of melanoma as thoroughly described by Shain et al 
(28, 29). 
Alongside cyclin D1, genetic alterations leading to acquisition of invasive behaviour have 
been thoroughly investigated. Loss of the cyclin dependent kinase inhibitor 2A (CDKN2A) 
tumour suppressor gene is the most common acquired genetic change in invasive 
melanoma (5). Bastian et al described the mechanism of melanoma initiation as a result 
of bi-allelic loss of CDKN2A, and consequently p16INK4A, via activation of BRN2, a 
transcription factor downstream of CDKN2A (30). Further investigations will be necessary 
to fully elucidate all aspects of invasion, thereby possibly uncovering new prognostic 
markers.
Inevitably, the results of our study need to be interpreted with certain limitations in mind. 
Matching of the two main groups (MTM and NMTM) was achieved for most 
characteristics, except for age, subtype and Breslow thickness. Exclusion of roughly 50% 
of all samples after acquisition from external laboratories for above mentioned reasons 
resulted in this unfortunate imbalance of subgroups regarding certain aspects. However, 
and most importantly, we do believe that the difference in Breslow thickness between the 
MTM and NMTM group does not represent a significant confounder of our main findings 
for two reasons. First, dermal Ki-67 expression retained its prognostic value also when 
Breslow thickness was taken into account in a multivariate analysis. Second, we did not 
detect any correlation between dermal Ki-67 expression and Breslow thickness, 
particularly not in the MTM subgroup in which median Breslow was increased.
In this context, discrepancy in Breslow measurement has to be addressed briefly. Our 
values for tumour thickness differed in a surprising number of patients when external 
samples were re-evaluated. This is particularly of importance if the mismeasurement 
leads to “understaging” of disease. These findings underline that a multi-eye principle is 










This article is protected by copyright. All rights reserved
In conclusion, we found an association of dermal Ki-67 expression with an increased risk 
of metastasis development in thin primary melanomas. The usefulness of Ki-67 
expression as a prognostic marker should be considered in clinical practice and could be 
enhanced through combination with other methods. Although our findings suggest a 
potential role of cyclin D1 during early invasion of melanoma cells, expression of this 
protein alone does not appear to be of prognostic significance.
Figure 1: Illustration of increased epidermal cyclin D1 expression in thin invasive 
melanoma (A, B) compared to in situ melanoma (C, D). A-D: 100x magnification; A+C: 
H&E stain, B+D: Cyclin D1 stain.
Figure 2: Increased frequencies of dermal Ki-67 positive tumour cells were found in 
metastatic (A - C) compared to non-metastatic (D - F) thin melanomas (P = 0.001).
Supplementary Figure 1: Flow chart of sample acquisition. 
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In situ (n = 22) P
MTM / NMTM
AJCC Stage IV 28 (66.7%)
AJCC Stage III 14 (33.3%)
Female 15 (35.7%) 28 (58.3%) 11 (50%)
Male 27 (64.3%) 20 (41.7%) 11 (50%)
0.032 †
Mean age at first 
diagnosis [y]
49.2
(95% CI = 44.8 - 53.7)
62.9
(95% CI = 58.2 - 67.5)
71.5






(95% CI = 0.72 - 0.84)
0.80
(95% CI = 0.74 - 0.86)
0.59
(95% CI = 0.55 - 0.63)
0.58
(95% CI = 0.53 - 0.62)
< 0.001 °
Histological subtype
SSM 24 (57.1%) 20 (41.7%) 11 (50%)
NMM 0 2 (4.2%) 0
ALM 3 (7.1%) 3 (6.2%) 0
LMM 1 (2.4%) 6 (12.5%) 11 (50%)






Head/Neck 7 (16.7%) 7 (14.6%) 1 (4.6%)
Upper extremities 4 (9.5%) 11 (22.9%) 1 (4.6%)
Lower extremities 12 (28.6%) 15 (31.2%) 1 (4.6%)
Trunk 17 (35.7%) 12 (25%) 2 (9%)
Acra 4 (9.5%) 3 (6.3%) 0
Unknown 0 0 17 (77.2%)
0.44 †
Mitoses / mm2
< 1 31 (73.8%) 39 (81.3%)
≥ 1 11 (26.2%) 9 (18.7%)
0.4 †
Ulceration
Present 2 (4.8%) 5 (10.4%)
Absent 37 (88.1%) 41 (85.4%)
Unknown 3 (7.1%) 2 (4.2%)
0.45 †
SLNB
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negative 7 (16.7%) 6 (12.5%)
Not performed 26 (61.9%) 42 (87.5%)
Marked Inflammation
Present 17 (40.5%) 20 (41.7%)
Absent 25 (59.5%) 28 (58.3%)
Abbreviations: SSM = superficial spreading melanoma, NMM = nodular melanoma, ALM = acral 
lentiginous melanoma, LMM = lentigo maligna melanoma. †: X
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In situ (n = 22) In situ vs. invasive * Non-metastatic vs. 
metastatic
Cyclin D1 intensity
None (0) 2 (4.8%) 0 0
Weak (1) 8 (19%) 9 (18.8%) 9 (40.9%)
Intermediate (2) 20 (47.6%) 16 (33.3%) 11 (50%)
Strong (3) 12 (28.6%) 23 (47.9%) 2 (9.1%)
P = 0.025
Cyclin D1 positive cells epidermal
0 1 (2.4%) 0 0
1% 2 (4.8%) 1 (2.1%) 1 (4.6%)
1 - 10% 7 (16.7%) 10 (20.8%) 14 (63.5%)
10 - 33% 19 (45.1%) 21 (43.8%) 5 (22.7%)
33 - 66% 7 (16.7%) 12 (25%) 2 (9.2%)
> 66% 4 (9.5%) 4 (8.3%) 0
NA 2 (4.8%) 0 0
P = 0.003 P = 0.611
Cyclin D1 positive cells dermal
0 9 (21.4%) 10 (20.8%)
1% 4 (9.5%) 6 (12.6%)
1 - 10% 11 (26.2%) 16 (33.3%)
10 - 33% 9 (21.4%) 10 (20.8 %)
33 - 66% 3 (7.2%) 2 (4.2 %)
> 66% 0 0
NA 6 (14.3%) 4 (8.3%)
P = 0.883
Allred score epidermal
None (0) 1 (2.4%) 0 0
Weak (1 - 2) 1 (2.4%) 1 (2.1%) 1 (4.6%)
Intermediate (3 - 5) 24 (57.2%) 22 (45.8%) 18 (81.8%)
Strong (6 - 8) 14 (33.2%) 25 (52.1%) 3 (13.6%)
NA 2 (4.8%) 0 0
P = 0.588
Allred score dermal
None (0) 1 (2.4%) 0
Weak (1 - 2) 11 (26.2%) 8 (16.7%)
Intermediate (3 - 5) 17 (40.4%) 27 (56.2%)
Strong (6 - 8) 7 (16.7%) 9 (18.8%)
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Ki-67 positive cells epidermal
≤ 20% 13 (30.9%) 23 (47.9%) 10 (45.4%)
≥ 20% 27 (64.3%) 25 (52.1%) 12 (54.6%)
NA 2 (4.8%) 0 0
P = 0.699 P = 0.148
Ki-67 positive cells dermal
≤ 20% 18 (42.8%) 38 (79.1%)
≥ 20% 12 (28.6%) 4 (8.3%)
NA 12 (28.6%) 6 (12.6%)
P = 0.001
Ki-67 + Cyclin D1 epidermal
Low (0 - 4) 13 (31%) 20 (41.7%) 21 (95.4%)
High (5 - 7) 25 (59.5%) 28 (58.3%) 1 (4.6%)
NA 4 (9.5) 0 0
P = 0.386
Ki-67+ Cyclin D1 dermal 
Low (0 - 4) 19 (45.2%) 38 (79.2%)
High (5 - 7) 8 (19.1%) 1 (2.1%)
NA 15 (35.7%) 9 (18.7%)
P = 0.003
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Table 3: Epidermal Cyclin D1 expression in different subtypes
Epidermal Cyclin D1 expression in different subtypes
P †








































† Fisher’s exact test
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